Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mokryun L. Baek"'
Autor:
Wangie Yu, Yunyun Chen, Nagireddy Putluri, Abdullah Osman, Cristian Coarfa, Vasanta Putluri, Abu H. M. Kamal, Jennifer Kay Asmussen, Panagiotis Katsonis, Jeffrey N. Myers, Stephen Y. Lai, Wuhao Lu, Clifford C. Stephan, Reid T. Powell, Faye M. Johnson, Heath D. Skinner, Jawad Kazi, Kazi Mokim Ahmed, Linghao Hu, Addison Threet, Matthew D. Meyer, James A. Bankson, Tony Wang, Jack Davis, Kirby R. Parker, Madison A. Harris, Mokryun L. Baek, Gloria V. Echeverria, Xiaoli Qi, Jin Wang, Andy I. Frederick, Alex J. Walsh, Olivier Lichtarge, Mitchell J. Frederick, Vlad C. Sandulache
Publikováno v:
British Journal of Cancer. 128:2013-2024
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::154d3749722bfad6e9f8084a8ee3b730
https://doi.org/10.1038/s41416-023-02253-7
https://doi.org/10.1038/s41416-023-02253-7
Autor:
Katherine E. Pendleton, Mokryun L. Baek, Junegoo Lee, Lin Tan, Hannah L. Johnson, Lacey E. Dobrolecki, James P. Barrish, Michael T. Lewis, Philip L. Lorenzi, Fabio Stossi, Gloria V. Echeverria
Publikováno v:
Cancer Research. 83:P6-11
Background: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype for which limited targeted therapies are available. Therefore, conventional chemotherapy remains the backbone of standard neoadjuvant treatment (NACT) for TNBC pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57f1fa69cc4206aa91aa6feea094f5ab
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-15
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-15
Autor:
Mokryun L. Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily B. Goff, Lin Tan, Sara A. Martinez, Iqbal Mahmud, Tao Wang, Matthew D. Meyer, Bora Lim, James P. Barrish, Weston Porter, Philip L. Lorenzi, Gloria V. Echeverria
Publikováno v:
Oncogene
Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in approximately 45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bafa58e4c0d1f2889d32411063d87891
https://europepmc.org/articles/PMC10069007/
https://europepmc.org/articles/PMC10069007/
Autor:
Mokryun L. Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily B. Goff, Lin Tan, Sara A. Martinez, Tao Wang, Matthew D. Meyer, Bora Lim, James P. Barrish, Weston Porter, Philip L. Lorenzi, Gloria V. Echeverria
Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in approximately 45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::717625ad35b5c6c96520bf5e771ec8c7
https://doi.org/10.1101/2022.02.25.481996
https://doi.org/10.1101/2022.02.25.481996